When it comes to Alzheimer’s and postmenopausal women, there is good evidence now that women in menopause are at a higher risk to develop Alzheimer’s due to a 1.5-fold increase in beta-amyloid (Ref. 7).
This is due to low estrogen and it has been shown that low dose estrogen replacement is effective in experimental animals as well as in humans to significantly improve Alzheimers symptoms. This is thought to occur because of a toning down of the beta-amyloid peptide production. However, recent data found that estrogen replacement therapy leads to a higher risk of heart attacks, strokes, breast cancer and uterine cancer. For this reason physicians are more cautious now ordering postmenopausal hormone replacement, particularly estrogen only (without progesterone balance). Discuss these issues with your doctor, if this affects you.
Genetic testing at the present time to predict who will develop Alzheimers is not reliably possible, as Ref. 8 has pointed out. This reference stresses the point that it is “useless” to attempt to do some of the commercially available tests, as they simply do not deliver what they promise. However, once Alzheimers has developed, there are some therapies available as is pointed out in the Alzheimers treatment section. There are also measures of preventing Alzheimers that are discussed at the end of the treatment section.
Two newer developments are important to mention.
1. Detoxification of heavy metals is one step that will prevent Alzheimer’s from occurring and from allowing Alzheimer’s to deteriorate further. Particularly heavy metals like mercury, aluminum and lead have been linked to deteriorate and partially cause Alzheimer’s disease.
2. Bioidentical hormones, given early enough based on deficiencies determined with hormone tests, can make an enormous difference in terms of preventing Alzheimer’s. As I have summarized under this link this new approach of bioidentical hormone replacement has other beneficial effects (antiaging, improvement of sex life, recovery of lost energies etc.). As this link explains, Dr. Rimkus has replaced hormone deficient aging men with estradiol and progesterone (typically regarded as female hormones), but at the doses of about 1/4 of the dose used for women. In my mind this is a revolutionary approach, but makes biological sense as both men and women have estrogen and progesterone receptors (in addition to testosterone receptors). The estrogen receptors of men’s brains likely need the minute amounts of estradiol to prevent Alzheimers and senile forgetfulness, but too little research has been done in North American universities with regard to bioidentical hormones as they cannot be patented. Testosterone is now also being recognized as contributing to prevention of Alzheimer’s disease when used as part of a bioidentical hormone replacement program and has been shown to not cause cancer.
1. OL Lopez et al. Neurology 2000 Dec 55(12):1863-1869.
2. K Yasojima et al. Brain Res 2000 DEC 887(1):80-89.
3. A Kontush et al. FreeRadicBiol Med2001Jan30(1): 119-128.
4. H Vanderstichele et al. Amyloid 2000Dec7(4):245-258.
5. Neely et al. Lipids 2000 Nov35(11):1249-1257.
6. RA Yokel Neurotoxicology 2000 Oct21(5):813-828.
7. Petanceska et al. Exp Gerontol 2000 Dec 35 (9-10):1317-1325.
8. MB Liddell et al. Brit J Psychiatry 2001 Jan 178: 7-11.
9. Sramek et al.ExpertOpinInvestigDrugs2000Apr9(4):899-915.
10.K Kosaka et al. Neuropathology 2000 March 20(1): 1-7.
11.V Haroutunian et al.Arch Neurol 2000 Aug57(8):1145-1150.
12. C Puckett et al. Am J Hum Genet 1991Aug49(2):320-329.
13. M Haltia Ann Med 2000 Oct 32(7): 439-500.
14. Ferri: Ferri’s Clinical Advisor: Instant Diagnosis and Treatment, 2004 ed., Copyright © 2004 Mosby, Inc.
15. Rakel: Conn’s Current Therapy 2004, 56th ed., Copyright © 2004 Elsevier